Annovis Bio, Inc. (ANVS)

Market Cap	103.67M
Revenue (ttm)	n/a
Net Income (ttm)	-47.53M
Shares Out	11.17M
EPS (ttm)	-5.75
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	39,033,246
Open	5.33
Previous Close	5.27
Day's Range	4.53 - 12.51
52-Week Range	4.53 - 22.49
Beta	1.77
Analysts	Strong Buy
Price Target	31.25 (+236.75%)
Earnings Date	Aug 13, 2024

About ANVS

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 29, 2020
• Employees: 6
• Stock Exchange: NYSE
• Ticker Symbol: ANVS

Analyst Forecast

According to 4 analysts, the average rating for ANVS stock is "Strong Buy." The 12-month stock price forecast is $31.25, which is an increase of 236.75% from the latest price.

Price Target

$31.25

(236.75% upside)

Analyst Consensus: Strong Buy